Abstract Body

Background

Differences in injection site reaction (ISR) profiles are an important consideration when choosing long-acting injectable (LAI) antiretrovirals. Nodules and indurations are of interest given their potential for long-lasting inflammatory effects and inadvertent disclosure of therapy if visible, yet data remains lacking on their characteristics. The CLARITY study (NCT06970223) provides detailed evaluation of ISRs after a single-dose each of cabotegravir IM (CAB) and lenacapavir SC (LEN) injections.

Methods

CLARITY is an open-label, randomized crossover study (CAB IM and LEN SC, 1 dose each) in 63 adults without HIV. The primary endpoint was ISR acceptability 7 days after injection using the Perception of Injection (PIN) questionnaire. Secondary endpoints evaluate participant preference and ISR incidence, severity and duration through 6-month follow-up. Size and inflammatory components of ISRs are assessed using a combination of 2D photography and 3D ultrasound. Here we report detailed visible/palpable ISR events of interest up to 22 days after administration of each drug.

Results

A diverse group of 63 participants were enrolled including 33% Female, 38% Hispanic, and 29% Black. Previously this study showed higher ISR acceptability and preference for a single dose of CAB over LEN. Frequency (LEN, n=538 vs CAB, n=123) and grade (≥ Grade 2 LEN 56.5% vs CAB 29.6%) of ISRs were higher with LEN compared to CAB injections (Table). Participants experienced more visible/palpable ISRs of interest with LEN vs CAB, with induration reported in 87% (54/62) vs 18% (11/61) and nodules in 74% (46/62) vs 33% (20/61), respectively. The number of visible nodules (CAB 0 vs LEN 21) and indurations (CAB 11 vs LEN 76) was also higher with LEN injections. Median nodule diameter was 4cm (Range 2-7 cm) for LEN (n=92) vs 2.4cm (Range 1.5-5.5 cm) for CAB (n=20) and the median induration surface area was 9.8 cm2 (Range 6.3-38.5 cm2) for LEN (n=94) vs 10.5 cm2 (Range 6.3-48 cm2) for CAB (n=11) injections. More participants reported not being bothered by hardening (or a bump) at the injection site with CAB vs LEN [Not bothered at all; CAB 71% (43/61) vs 22% LEN (n=13/60)] at 7 days post dose.

Conclusions

The CLARITY study found significant differences in ISRs between CAB and LEN injections after a single dose of each, including more visible/bothersome ISRs with LEN. These data are important for individuals and providers to make informed choices regarding LAI antiretrovirals.

Table or Figure